Source: Medthority

Cardurion: Imara Inc.to sell IMR 687 to Cadurion Pharma.

IMARA Inc., entered into an Asset Purchase Agreement with Cardurion Pharmaceuticals, Inc., providing for the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program.

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
Peter S. Lawrence's photo - President & CEO of Cardurion

President & CEO

Peter S. Lawrence

CEO Approval Rating

88/100

Read more